



**INVESTIGATION OF
THE BINDING SPECIFICITY OF IGF-1R
USING MONOCLONAL ANTIBODIES**

By

Mehrnaz Keyhanfar, Pharm.D.

**A thesis submitted to the University of Adelaide, South Australia
in fulfilment of the requirements for the degree of
Doctor of Philosophy**



**School of Molecular and Biomedical Science
The University of Adelaide
Adelaide, South Australia, 5005**

September 2005

Abstract

The insulin-like growth factor type one receptor (IGF-1R) plays a critical role in cancer. The receptor is over expressed in many tumours and mediates growth, motility, and survival from apoptosis. Several studies have shown that the inhibition of IGF-1R's expression or its function blocks tumour growth or metastasis, and also enhances sensitivity to cytotoxic drugs and irradiation. To date, IGF-1R is widely considered as a very promising target for cancer treatment.

Among different techniques for targeting IGF-1R, blocking the receptor with specific monoclonal antibodies (MAbs) is an attractive way to inhibit the receptor signalling. In addition, antibodies specific for the IGF-1R are potential diagnostic reagents as the IGF-1R is overexpressed in several cancers. A similar approach has been successfully utilized in the treatment of breast cancer using Herceptin, which is a humanised MAb against human epidermal growth factor receptor-2.

In this thesis, two high affinity murine MAbs against IGF-1R namely 7C2 and 9E11 were isolated and cloned. To obtain these MAbs, s-IGF-1R (the soluble extracellular part of the IGF-1R, amino acids 1-906) was used as an immunogen. These MAbs were IgG1κ isotype and did not cross react with either insulin receptor isoform IR-A or IR-B. MAbs 7C2 and 9E11 successfully detected IGF-1R in a number of immunoassays such as in enzyme linked immunosorbent assays (ELISAs), flow cytometry and immunohistochemistry. The MAbs also immunoprecipitated IGF-1R from lysates of cells overexpressing recombinant IGF-1R. Both MAbs 7C2 and 9E11 showed high affinity to the s-IGF-1R. The binding affinities of the MAbs 7C2 and 9E11 to s-IGF-1R were 0.5 ± 1.6 nM and 2.1 ± 0.4 nM, respectively. The sequences of the variable regions of these MAbs' heavy and light chains were also described in this study. Comparison of the CDR sequences of the MAbs with those of other MAbs against the IGF-1R showed that MAbs 7C2 and 9E11 each had a unique sequence.

During this research it was found that MAbs 7C2 and 9E11 blocked the binding of IGF-I to the IGF-1R, but did not show an inhibitory effect on the binding of IGF-II to this receptor. Moreover, epitope mapping of MAbs 7C2 and 9E11 revealed that they both bound to the cysteine-rich domain of the receptor. These findings support a previous study, which demonstrated that the cysteine-rich domain of IGF-1R is critical for specific binding of IGF-I but not IGF-II to the receptor.

In this thesis, further epitope mapping studies on MAbs 7C2 and 9E11 using alanine mutants of the IGF-1R in the cysteine-rich domain are reported. The results showed that amino acids F241, F251 and F266 were involved in binding to both MAbs 7C2 and 9E11. On the other hand, another study showed that amino acids F241 and F251 were crucial for IGF-I binding to the receptor. Therefore, binding to these two amino acids by MAbs 7C2 and 9E11 is most likely responsible for the selective blocking of IGF-I but not IGF-II to the receptor.

Competition experiments performed during this research revealed that the chimeric IGF analogues IGF-ICII (IGF-I with IGF-II C domain) and IGF-IICI (IGF-II with IGF-I C domain) behaved like IGF-II and IGF-I, respectively in their ability to inhibit the binding of MAbs 7C2 and 9E11 to s-IGF-1R. These findings imply that out of all four domains of IGF-I, it is the C domain, which binds to residues in IGF-1R that form the epitope for MAbs 7C2 and 9E11. Because in the C domain of IGF-I, amino acids R36 and R37 and also Y31 have been shown to be important for binding to IGF-1R, it could be proposed that the binding of the IGF-I C domain to the IGF-1R cysteine-rich domain is through binding amino acids R36, R37 and Y31 of IGF-I to residues F241 and F251, or to the nearby residues, which are sterically affected by the presence of the MAbs binding to the receptor.

In this research, *in vitro* studies, using MAbs as anti-cancer reagents revealed that both MAbs 7C2 and 9E11 inhibited the proliferation of colon cancer cell (HT-29) induced by IGF-I and IGF-II. However, the neutralizing effect for IGF-II was less potent than for IGF-I. Since the MAbs did not inhibit binding of IGF-II to the receptor, their effect on IGF-II induced cell proliferation could be claimed to be due to an indirect effect. This is consistent

with the *in vitro* result for the receptor down-regulation experiment, which showed that 24 h incubation of breast cancer cells (MCF-7) with MAbs 7C2 and 9E11, significantly reduced the IGF-1R expression. In this study it was also shown that MAbs 7C2 and 9E11 inhibited MCF-7 cells migration induced by IGF-I. This could indicate a potential anti-metastatic property of MAbs 7C2 and 9E11.

Taken together, the *in vitro* effects of MAbs 7C2 and 9E11 reported in this thesis revealed that they had inhibiting effects on cancer cell proliferation and migration and they also induced IGF-1R down-regulation. Therefore, they could be potentially valuable prospects for cancer treatment if humanised.

Finally, MAbs 7C2 and 9E11 could be used as diagnostic reagents to detect IGF-1R in cells or tissue samples in a range of immunoassays as mentioned earlier. Due to the IGF-1R overexpression in several cancer tumours, MAbs 7C2 and 9E11 could be utilized for malignant tumour recognition. Furthermore, as another application, these MAbs could also be used to identify tumours overexpressing the IGF-1R, allowing tailored anti-cancer treatment including an IGF-1R blocking agent.

Abstract.....	I
Statement of Originality.....	IV
Acknowledgments.....	V
Table of Content.....	VII
List of Figures.....	XI
List of Tables.....	XIV
List of Publications.....	XV
List of Abbreviations.....	XVII

1. Literature Review.....	1
1.1. Introduction.....	1
1.2. Introduction to the IGF System.....	2
1.3. IGF Ligands.....	4
1.3.1. IGF Ligand Binding Characterisation.....	9
1.4. IGFBP Structure and Function.....	9
1.5. The Structure and Function of the Receptors.....	11
1.5.1. IR Function and Structure.....	12
1.5.2. IGF-1R Function and Structure.....	14
1.5.2.1. The IGF-1R and IR Ectodomain Structure.....	20
1.5.2.2. IGF-1R Signaling.....	22
1.5.2.3. IGF-1R Residues Involved in IGF Binding.....	24
1.5.2.4. IGF Ligand Residues Involved in IGF-1R Binding.....	29
1.6. The IGF System and Cancer.....	34
1.6.1. IGF Ligands and Cancer.....	34
1.6.2. IGFBPs and Cancer.....	36
1.6.3. The IGF-2R and Cancer.....	37
1.6.4. The Roles of IR Isoforms and Hybrid Receptors in Cancer.....	38
1.6.5. The Role of IGF-1R in Cancer.....	39
1.7. Different Strategies for Targeting IGF-1R as an Anti-cancer Therapy.....	40
1.8. Antibodies.....	41
1.8.1. Antibodies Structure.....	41
1.8.2. Antibodies Application.....	46
1.8.3. Monoclonal Antibodies.....	47
1.8.4. Epitope Mapping.....	48
1.8.4.1. Methods Used to Localize Epitopes in Proteins.....	49
1.8.5. Clinical Applications of Monoclonal Antibodies.....	50
1.9. Monoclonal Antibodies Directed Against the IGF-1R.....	51
1.10. Aims and Experimental Strategy.....	58
2. Materials and General Methods.....	60
2.1. Materials.....	60
2.1.1. General Materials.....	60
2.1.2. Chemicals Reagents.....	60
2.1.3. Antibodies.....	63
2.1.4. Bacterial Strains.....	64
2.1.5. Tissue Culture Cell Lines.....	64
2.1.6. Tissue Culture Solutions.....	65
2.1.7. Media for Growing Cells <i>in vitro</i>	65
2.1.8. Primers.....	65
2.1.9. Commercial Kits.....	66

2.1.10. Solutions	66
2.1.11. Computer Applications	68
2.2. General Methods	68
2.2.1. Culture of Mammalian Cells.....	69
2.2.2. Protein Chemistry Techniques.....	69
2.2.2.1. ELISA Test for Detection of s-IGF-1R	69
2.2.2.2. ELISA Test for Detection of Antibodies Against IGF-1R	70
2.2.2.3. Protein Concentration	70
2.2.2.4. Flow Cytometry.....	71
2.2.2.5. SDS-PAGE Electrophoresis and Gel Staining.....	72
2.2.2.6. Electroblot and Western Immuno-Detection	72
2.2.2.7. Immunoprecipitation of Proteins from Cell Lysates.....	73
2.2.3. Molecular Biology Techniques.....	74
2.2.3.1. Agarose Gel Electrophoresis	74
2.2.3.2. Preparation of DH5- α Competent Cells	74
2.2.3.3. Transformation of Bacteria by Heat Shock	75
2.2.3.4. Glycerol Stocks.....	75
2.2.3.5. Bacterial Culture	75
2.2.3.6. Purification of Plasmid DNA.....	75
2.2.3.7. DNA Sequencing	76
3. Production, Characterisation and Sequencing of the Variable Regions of Mouse Monoclonal Antibodies.....	77
3.1. Introduction.....	77
3.2. Methods for General Characterisation of MAbs.....	80
3.2.1. Animal Ethics	80
3.2.2. Antigen Production and Purification	80
3.2.2.1. Culture and Purification of s-IGF-1R	80
3.2.2.2. ELISA Test for Detection of Purified s-IGF-1R	81
3.2.3. Hybridoma Production.....	81
3.2.3.1. Immunisation of the Mice.....	81
3.2.3.2. ELISA Test for Detection of Antibodies in Plasma from Immunised Mice	82
3.2.3.3. Preparation of Lymphocytes from Mouse Spleen	83
3.2.3.4. Preparation of Myeloma Cells for Fusion.....	83
3.2.3.5. Fusion of Myeloma Cells with Spleen Lymphocytes.....	83
3.2.3.6. Detection of Antibodies Against s-IGF-1R in the Hybridoma Culture Mediums	85
3.2.3.7. Cloning by Limiting Dilution of Hybridoma.....	85
3.2.3.8. Freezing and Thawing of Hybridoma Cells.....	86
3.2.4. Determination of Immunoglobulin Isotypes.....	86
3.2.5. Screening of Positive Hybridomas for Binding to the IGF-1R Cell Surface Using Flow Cytometry	87
3.2.6. Large-Scale Production of the Selected MAbs.....	87
3.2.7. Purification of Antibody and Determination of the Antibody Concentration	88
3.2.8. SDS-PAGE Electrophoresis and Gel Staining of Purified MAbs	89
3.2.9. Freeze-Drying of the Purified MAbs	89
3.2.10. Immunoprecipitation and Western Blot Analysis.....	89
3.2.11. Immunoblotting of the IGF-1R Using the Generated MAbs.....	90
3.2.12. Using the MAbs in Immunohistochemistry	91
3.2.12.1. Immunohistochemistry on Frozen Cells.....	91
3.2.12.2. Immunohistochemistry on Frozen Skin Sections	92
3.2.12.3. Immunohistochemistry on Paraffin-Embedded Skin Sections	93
3.3. Method for CDR Sequencing of MAbs Heavy and Light Chains	94

3.3.1. Extraction of Total Cellular RNA.....	95
3.3.2. Purification of RNA Samples.....	96
3.3.3. Electrophoresis of Purified RNA Samples on Agarose Gel.....	96
3.3.4. Quantification of Purified RNA.....	96
3.3.5. Synthesis of cDNA.....	97
3.3.6. PCR Amplification of cDNA Encoding the Variable Region of Heavy or Light Chain of the MAb.....	97
3.3.7. Agarose Gel Electrophoresis of PCR Products.....	98
3.3.8. Purification of DNA Fragments from the Positive PCR Products.....	98
3.3.9. Ligation of Variable Region cDNAs of MABs into pGEM-T Easy Vector.....	98
3.3.10. Transformation of the Ligated Plasmids into <i>E. coli</i> DH5 α	99
3.3.11. Small-Scale Production of Plasmid DNA.....	99
3.3.12. Digestion of Purified Plasmid DNA.....	100
3.3.13. DNA Sequencing.....	100
3.4. Results and Discussion for General Characterisation of MABs.....	100
3.4.1. Hybridoma Screening and Isotyping.....	100
3.4.2. Flow Cytometry Results.....	102
3.4.3. Large Scale Production and Purification of MABs.....	104
3.4.4. The Activity of Freeze-Dried Monoclonal Antibodies.....	104
3.4.5. Immunoprecipitation and Immunoblotting of the IGF-1R.....	105
3.4.6. Immunohistochemistry Results.....	108
3.5. Results for CDR Sequencing.....	110
3.5.1. RNA Extraction.....	110
3.5.2. PCR Amplification.....	111
3.5.3. Ligation.....	112
3.5.4. Sequencing Results.....	112
3.6. Summary and Final Discussion.....	116
4. Binding Analysis and Epitope Mapping of MABs 7C2 and 9E11 to IGF-1R.....	121
4.1. Introduction.....	121
4.2. Methods.....	125
4.2.1. IGF-1R Competition Binding Assay.....	125
4.2.2. BIAcore Analysis of MABs and s-IGF-1R Interactions.....	127
4.2.2.1. Surface Preparation.....	127
4.2.2.2. Kinetic Assays of Anti-IGF-1R MABs (7C2, 9E11 and α IR-3) Binding to the s-IGF-1R.....	127
4.2.2.3. BIAcore Analysis of s-IGF-1R and MABs Interaction in Presence of IGF-I or IGF-II.....	128
4.2.2.4. BIAcore Analysis of s-IGF-1R and MABs Interaction in the Presence of IGF Chimeras (IGF-ICII and IGF-IICI).....	129
4.2.2.5. Mass Transfer Control Experiment.....	129
4.2.3. Epitope Mapping by Flow Cytometry Analysis Using Chimeric Receptors.....	130
4.2.4. Epitope Mapping by Competition Assay Between Different MABs to IGF-1R...132	132
4.2.4.1. The Fragmentation of IgG to Fab Using Papain.....	132
4.2.4.2. Europium Labelling of Fab.....	133
4.2.4.3. Competition Binding Analysis Between MABs Against the IGF-1R.....	134
4.2.5. Epitope Mapping Using Alanine Mutants of the IGF-1R.....	135
4.2.5.1. Transfection Methods.....	135
4.2.5.2. ELISA to Determine the Expression of the Recombinant Receptors.....	136
4.2.5.3. Europium Binding Assay for Epitope Mapping of the MABs by Alanine Mutants of the IGF-1R.....	137
4.2.5.4. Sequencing the Plasmids Containing cDNAs for Alanine Mutants of IGF-1R.....	138

4.3. Results.....	139
4.3.1. Effect of the MAbs on IGF-1R Competition Binding Assay	139
4.3.2. BIAcore Results	141
4.3.2.1. Kinetic Analysis of the MAb and s-IGF-1R Binding.....	142
4.3.2.2. Mass Transfer Control	144
4.3.2.3. The Effects of IGF-I and IGF-II on Binding s-IGF-1R to the MAbs.....	145
4.3.2.4. The Effects of IGF Chimeras (IGF-ICII and IGF-IICI) on Binding s-IGF-1R to the MAbs	149
4.3.3. Results for Flow Cytometry Analysis on Chimeric Receptors.....	151
4.3.4. Fragmentation of MAbs and Europium Labelling of the Fab	153
4.3.5. Competition of Eu-7C2 and Eu-9E11 with other MAbs	154
4.3.6. IGF-1R Alanine Mutant Expression.....	155
4.3.7. ELISA on s-IGF-1R.....	156
4.3.8. Identification of MAbs Binding Epitope	157
4.3.9. Sequencing of the Plasmids Containing IGF-1R Mutants.....	158
4.4. Discussion.....	160
4.4.1. Binding Studies.....	160
4.4.2. Epitope Mapping with Chimeric Receptors.....	161
4.4.3. Epitope Mapping with Alanine-Scan Receptor Mutants	162
4.4.4. Epitope Mapping with a Cysteine-Rich Domain Chimera	163
4.4.5. MAb Epitopes and IGF Binding to IGF-1R	166
4.4.6. Structural and Functional Epitope on the IGF-1R.....	169
4.4.7. Interaction of IGF-1R with IGF-I and IGF-II.....	171
4.4.8. Comparing the Affinity of MAbs 7C2 and 9E11 to other Antibodies Against the IGF-1R.....	173
5. Biological Effects of the MAbs <i>in vitro</i>.....	175
5.1. Introduction.....	175
5.2. Methods	177
5.2.1. Cell Proliferation Assay.....	177
5.2.2. Cell Migration Assays	178
5.2.3. Analysis of the IGF-1R Down-Regulation	179
5.3. Results.....	180
5.3.1. Effect of the MAbs on HT-29 Cell Proliferation.....	180
5.3.2. Effect of the MAbs on MCF-7 Cell Migration.....	184
5.3.3. Effect of the MAbs on IGF-1R Down-Regulation in MCF-7Cells	185
5.4. Discussion.....	186
6. Final Discussion, Future Applications and Directions.....	190
6.1. Discussion.....	190
6.2. Summary of Findings.....	190
6.2.1. The Selective Blocking Activity of the MAbs and Epitope Mapping.....	191
6.2.2. Affinity of the MAbs	193
6.2.3. The Biological Effects of MAbs.....	193
6.3. Future Applications.....	194
6.4. Future Directions	197
6.5. Conclusion	199
References.....	201